Literature DB >> 16567017

A decade of modeling Alzheimer's disease in transgenic mice.

Eileen McGowan1, Jason Eriksen, Michael Hutton.   

Abstract

It has been over a decade since the first Alzheimer's disease (AD) transgenic mouse models were reported. These models have enabled dramatic advances in our understanding of the pathogenic mechanism in AD and of potential therapeutic approaches to tackling the inexorable clinical progression of the disease. In this article, we discuss the current status of AD mouse models and focus on recent work that has examined the development of the neuropathological lesions observed in AD (plaques and tangles). The relationship between these lesions, neurodegeneration and development of the clinical syndrome will be explored.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16567017     DOI: 10.1016/j.tig.2006.03.007

Source DB:  PubMed          Journal:  Trends Genet        ISSN: 0168-9525            Impact factor:   11.639


  108 in total

1.  Regulation of tau pathology by the microglial fractalkine receptor.

Authors:  Kiran Bhaskar; Megan Konerth; Olga N Kokiko-Cochran; Astrid Cardona; Richard M Ransohoff; Bruce T Lamb
Journal:  Neuron       Date:  2010-10-06       Impact factor: 17.173

Review 2.  Alzheimer's therapeutics: translation of preclinical science to clinical drug development.

Authors:  Alena V Savonenko; Tatiana Melnikova; Andrew Hiatt; Tong Li; Paul F Worley; Juan C Troncoso; Phil C Wong; Don L Price
Journal:  Neuropsychopharmacology       Date:  2011-09-21       Impact factor: 7.853

Review 3.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

4.  Gene delivery to postnatal rat brain by non-ventricular plasmid injection and electroporation.

Authors:  Dmitry A Molotkov; Alexey Y Yukin; Ramil A Afzalov; Leonard S Khiroug
Journal:  J Vis Exp       Date:  2010-09-17       Impact factor: 1.355

Review 5.  Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Authors:  Meaghan C Creed; Norton W Milgram
Journal:  Age (Dordr)       Date:  2010-04-20

6.  BACE1 gene deletion prevents neuron loss and memory deficits in 5XFAD APP/PS1 transgenic mice.

Authors:  Masuo Ohno; Sarah L Cole; Marina Yasvoina; Jie Zhao; Martin Citron; Robert Berry; John F Disterhoft; Robert Vassar
Journal:  Neurobiol Dis       Date:  2006-12-20       Impact factor: 5.996

7.  Danish dementia mice suggest that loss of function and not the amyloid cascade causes synaptic plasticity and memory deficits.

Authors:  Robert Tamayev; Shuji Matsuda; Mauro Fà; Ottavio Arancio; Luciano D'Adamio
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-22       Impact factor: 11.205

8.  Signal transduction in Alzheimer disease: p21-activated kinase signaling requires C-terminal cleavage of APP at Asp664.

Authors:  Thuy-Vi V Nguyen; Veronica Galvan; Wei Huang; Surita Banwait; Huidong Tang; Junli Zhang; Dale E Bredesen
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

Review 9.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 10.  Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Authors:  Kanae Iijima-Ando; Koichi Iijima
Journal:  Brain Struct Funct       Date:  2009-12-05       Impact factor: 3.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.